Mobile website
Clinical Research
Expression of osteopontin in breast cancer of different molecular subtypes and its clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To study the expression of osteopontin (OPN) in breast carcinoma of different molecular subtypes and its clinical significance. Methods： A total of 99 breast cancer samples were collected from patients who were treated during Jan. 2000 to Dec. 2003 in Changhai Hospital. Expression of ER, PR and HER-2 was detected by inmmnohistochemical staining, and the samples were categorized as follows：luminal A, luminal B, HER-2 over-expression subtype, and basal-like subtype. The expression of OPN in all molecular subtypes was detected by immunohistochemical-SP method, then the correlation of OPN expression with patients’ clinical and pathological features was analyzed. Results: According to the expression of ER, PR and HER-2 in 99 breast cancer patients, there were 45 luminal A, 27 luminal B, 14 HER-2 over-expression and 13 basal-like subtypes. The positive rates of OPN in luminal A, luminal B, HER-2 over-expression and basal-like subtypes were 22.2%, 29.6%, 71.4% and 61.5%, respectively. The positive rates of OPN in HER-2 over-expression and basal-like subtypes were significantly higher than those in luminal A and luminal B subtypes (P<0.01). The survival rate of patients with low OPN expression was significantly higher than that of patients with high OPN expression (P<0.01). Conclusion: OPN is highly expressed in basal-like and HER-2 over-expression subtypes of breast cancer, which indicates that OPN may be a useful indicator for prognosis of breast carcinoma.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 30870975)
Clc Number:
